Alopecia areata.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28300084)

Published in Nat Rev Dis Prim on March 16, 2017

Authors

C Herbert Pratt1, Lloyd E King2, Andrew G Messenger3, Angela M Christiano4, John P Sundberg2,5

Author Affiliations

1: Department of Genetic Resource Sciences, The Jackson Laboratory, Bar Harbor, Maine, USA.
2: Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
3: Department of Dermatology, Royal Hallamshire Hospital, Sheffield, UK.
4: Departments of Dermatology and Genetics &Development, Columbia University, New York, New York, USA.
5: Department of Research and Development, The Jackson Laboratory, 600 Main Street, Bar Harbor, Maine 04609-1500, USA.

Articles cited by this

(truncated to the top 100)

Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science (1998) 37.15

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med (2014) 3.54

Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature (2010) 2.85

The psychological impact of alopecia. BMJ (2005) 2.49

A statistical study and consideration of endocrine influences. J Invest Dermatol (1950) 2.25

Critical stages of hair development and pigmentation in the mouse. Physiol Zool (1951) 2.22

Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc (1995) 1.99

Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol (2001) 1.81

Alopecia areata in aging C3H/HeJ mice. J Invest Dermatol (1994) 1.78

Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am Acad Dermatol (2005) 1.75

Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol (2014) 1.73

Profile of alopecia areata in Northern India. Int J Dermatol (1996) 1.64

Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol (2006) 1.56

Spontaneous, heritable colitis in a new substrain of C3H/HeJ mice. Gastroenterology (1994) 1.56

Interventions for alopecia areata. Cochrane Database Syst Rev (2008) 1.55

Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation. J Am Acad Dermatol (2004) 1.53

The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action. Curr Genomics (2007) 1.47

Experimental induction of alopecia areata-like hair loss in C3H/HeJ mice using full-thickness skin grafts. J Invest Dermatol (1998) 1.46

Hair loss after routine immunizations. JAMA (1997) 1.43

Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J Am Acad Dermatol (2014) 1.43

Prevalence of adrenal insufficiency following systemic glucocorticoid therapy in infants with hemangiomas. Arch Dermatol (2009) 1.42

Alopecia areata and health-related quality of life: a systematic review and meta-analysis. Br J Dermatol (2016) 1.40

Vasoactive intestinal peptide, whose receptor-mediated signalling may be defective in alopecia areata, provides protection from hair follicle immune privilege collapse. Br J Dermatol (2016) 1.40

Adult-onset Alopecia areata is a complex polygenic trait in the C3H/HeJ mouse model. J Invest Dermatol (2004) 1.38

[Alopecia universalis in an adult after routine tetanus toxoid vaccine]. Med Clin (Barc) (2010) 1.37

Clinical and molecular diagnostic criteria of congenital atrichia with papular lesions. J Invest Dermatol (2002) 1.35

Histopathologic features of alopecia areata: a new look. Arch Dermatol (2003) 1.34

The pattern and profile of alopecia areata in Singapore--a study of 219 Asians. Int J Dermatol (2002) 1.33

Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun (2015) 1.32

Nodular fat necrosis and pancreatic diseases. Arch Dermatol (1961) 1.31

Atrichia caused by mutations in the vitamin D receptor gene is a phenocopy of generalized atrichia caused by mutations in the hairless gene. J Invest Dermatol (2001) 1.27

Management of alopecia areata. BMJ (2010) 1.25

Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol (1992) 1.23

The importance of myeloid-derived suppressor cells in the regulation of autoimmune effector cells by a chronic contact eczema. J Immunol (2007) 1.21

A 'hairy' privilege. Trends Immunol (2005) 1.21

MONILETHRIX: ITS OCCURRENCE IN SEVEN GENERATIONS, WITH ONE CASE THAT RESPONDED TO ENDOCRINE THERAPY. N Engl J Med (1963) 1.21

Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol (2006) 1.20

Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol (2007) 1.18

Nail changes in alopecia areata: frequency and clinical presentation. J Eur Acad Dermatol Venereol (2008) 1.17

Gene array profiling and immunomodulation studies define a cell-mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans. J Invest Dermatol (2002) 1.17

Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(-) cells promote systemic alopecia areata and CD4(+)/CD25(+) cells blockade disease onset in the C3H/HeJ mouse model. J Invest Dermatol (2005) 1.16

Alopecia areata: Clinical presentation, diagnosis, and unusual cases. Dermatol Ther (2011) 1.16

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine (2015) 1.15

Global burden of skin disease as reflected in Cochrane Database of Systematic Reviews. JAMA Dermatol (2014) 1.15

Mapping of the X-linked immune deficiency mutation (xid) of CBA/N mice. J Immunol (1980) 1.14

Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol (1998) 1.14

British Association of Dermatologists' guidelines for the management of alopecia areata 2012. Br J Dermatol (2012) 1.14

Comparison of alopecia areata in human and nonhuman mammalian species. Pathobiology (1998) 1.14

The genetic basis of alopecia areata: HLA associations with patchy alopecia areata versus alopecia totalis and alopecia universalis. J Investig Dermatol Symp Proc (1999) 1.13

Major locus on mouse chromosome 17 and minor locus on chromosome 9 are linked with alopecia areata in C3H/HeJ mice. J Invest Dermatol (2003) 1.12

The C3H/HeJ mouse and DEBR rat models for alopecia areata: review of preclinical drug screening approaches and results. Exp Dermatol (2008) 1.12

A new classification of alopecia areata. Dermatologica (1965) 1.09

Morphologic changes in pilosebaceous units and anagen hairs in alopecia areata. J Invest Dermatol (1958) 1.07

Overview of alopecia areata. J Investig Dermatol Symp Proc (2013) 1.07

Illness perceptions, coping and quality of life in patients with alopecia. Br J Dermatol (2009) 1.04

Transcriptional profiling in alopecia areata defines immune and cell cycle control related genes within disease-specific signatures. Genomics (2010) 1.04

Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol (2003) 1.04

Evidence that the bulge region is a site of relative immune privilege in human hair follicles. Br J Dermatol (2008) 1.03

Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice. J Invest Dermatol (2001) 1.02

Abnormal expression of class I and class II major histocompatibility antigens in alopecia areata: modulation by topical immunotherapy. J Invest Dermatol (1987) 1.02

Spontaneous alopecia areata-like hair loss in one congenic and seven inbred laboratory mouse strains. J Investig Dermatol Symp Proc (1999) 1.02

Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-α blocker agents: Report of five cases and review of the literature. J Eur Acad Dermatol Venereol (2011) 1.02

Antigenic competition as a therapeutic concept for alopecia areata. Arch Dermatol Res (1980) 1.02

Alopecia areata in children: a clinical profile. Pediatr Dermatol (2002) 1.02

Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. Am J Hematol (2015) 1.01

A case series of alopecia areata in children: impact of personal and family history of stress and autoimmunity. J Eur Acad Dermatol Venereol (2007) 1.01

Distinguishing mouse strains by proteomic analysis of pelage hair. J Invest Dermatol (2009) 1.01

Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. J Am Acad Dermatol (2011) 1.00

Autoimmune disease induction in a healthy human organ: a humanized mouse model of alopecia areata. J Invest Dermatol (2012) 1.00

[Comparative histologic studies in alopecia areata and scar-atrophy alopecia]. Arch Klin Exp Dermatol (1966) 0.99

Twice weekly 5 mg dexamethasone oral pulse in the treatment of extensive alopecia areata. J Dermatol (1999) 0.97

Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol (1992) 0.97

Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med (1995) 0.97

Differentiating inbred mouse strains from each other and those with single gene mutations using hair proteomics. PLoS One (2012) 0.96

Type 1 interferon signature in the scalp lesions of alopecia areata. Br J Dermatol (2010) 0.95

The DEBR rat: an animal model of human alopecia areata. Br J Dermatol (1991) 0.95

Expression of HLA-DR by anagen hair follicles in alopecia areata. J Invest Dermatol (1985) 0.94

Incidence of alopecia areata in lupus erythematosus. Arch Dermatol (1992) 0.94

Juvenile versus maturity-onset alopecia areata--a comparative retrospective clinical study. Clin Exp Dermatol (1989) 0.94

Immune privilege and the skin. Curr Dir Autoimmun (2008) 0.93

Nail changes in alopecia areata: incidence and pattern. Indian J Dermatol Venereol Leprol (2007) 0.93

The pathogenesis of alopecia areata. Br J Dermatol (1968) 0.93

Human leukocyte antigen class II alleles are associated with risk of alopecia areata. J Invest Dermatol (2007) 0.92

The genetic risk for alopecia areata in first degree relatives of severely affected patients. An estimate. Acta Derm Venereol (1992) 0.92

Genome-wide pooling approach identifies SPATA5 as a new susceptibility locus for alopecia areata. Eur J Hum Genet (2011) 0.92

Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance. J Invest Dermatol (2012) 0.91

Marie Antoinette syndrome. Arch Dermatol (2009) 0.91

Intralesional triamcinolone acetonide in alopecia areata amongst 62 Saudi Arabs. East Afr Med J (1994) 0.90

Alopecia areata. A follow-up investigation of outpatient material. Acta Derm Venereol (1969) 0.90

Increased expression of Cxcr3 and its ligands, Cxcl9 and Cxcl10, during the development of alopecia areata in the mouse. J Invest Dermatol (2012) 0.90

The epidemiology of childhood alopecia areata in China: a study of 226 patients. Pediatr Dermatol (2006) 0.89

Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: a clinical and immunopathologic evaluation. J Am Acad Dermatol (1997) 0.89

Alopecia areata in children: treatment with diphencyprone. Br J Dermatol (1996) 0.89

Pulse corticosteroid therapy for alopecia areata: study of 139 patients. Dermatology (2007) 0.89

Association of Vitiligo and Alopecia Areata With Atopic Dermatitis: A Systematic Review and Meta-analysis. JAMA Dermatol (2015) 0.89

Genetic variants in CTLA4 are strongly associated with alopecia areata. J Invest Dermatol (2011) 0.89

Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis. JAMA Dermatol (2016) 0.88

HLA in alopecia areata. Int J Dermatol (2000) 0.88

The DEBR rat model for alopecia areata. J Invest Dermatol (1991) 0.88

Alopecia areata in children: response to treatment with diphencyprone. Br J Dermatol (1991) 0.88